Insulet Corporation

BMV:PODD * Stock Report

Market Cap: Mex$373.2b

Insulet Valuation

Is PODD * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PODD * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PODD * (MX$5541.42) is trading above our estimate of fair value (MX$4162.98)

Significantly Below Fair Value: PODD * is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PODD *?

Key metric: As PODD * is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for PODD *. This is calculated by dividing PODD *'s market cap by their current earnings.
What is PODD *'s PE Ratio?
PE Ratio43.9x
EarningsUS$420.90m
Market CapUS$18.47b

Price to Earnings Ratio vs Peers

How does PODD *'s PE Ratio compare to its peers?

The above table shows the PE ratio for PODD * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average50.1x
688271 Shanghai United Imaging Healthcare
68.4x31.5%CN¥108.2b
STMN Straumann Holding
65.5x21.2%CHF 18.9b
STE STERIS
35x11.5%US$20.8b
SOON Sonova Holding
31.3x11.4%CHF 17.7b
PODD * Insulet
43.9x2.0%Mex$18.5b

Price-To-Earnings vs Peers: PODD * is good value based on its Price-To-Earnings Ratio (43.9x) compared to the peer average (50.1x).

Price to Earnings Ratio vs Industry

How does PODD *'s PE Ratio compare vs other companies in the Global Medical Equipment Industry?

10 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No. of Companies45PE020406080100+
10 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: PODD * is expensive based on its Price-To-Earnings Ratio (43.9x) compared to the Global Medical Equipment industry average (28.6x).

Price to Earnings Ratio vs Fair Ratio

What is PODD *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PODD * PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio43.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PODD *'s Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PODD * forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
Mex$5,729.79
0%
10.1%Mex$6,869.73Mex$4,727.99n/a22
Dec ’25n/a
Mex$5,625.13
0%
8.0%Mex$6,476.98Mex$4,781.11n/a22
Nov ’25n/a
Mex$4,886.37
0%
9.3%Mex$5,615.61Mex$3,645.22n/a21
Oct ’25n/a
Mex$4,750.87
0%
9.2%Mex$5,589.76Mex$3,628.44n/a21
Sep ’25n/a
Mex$4,667.05
0%
7.4%Mex$5,202.09Mex$3,645.41n/a21
Aug ’25n/a
Mex$3,970.91
0%
9.0%Mex$4,588.95Mex$3,144.28n/a21
Jul ’25n/a
Mex$3,970.91
0%
9.0%Mex$4,588.95Mex$3,144.28n/a21
Jun ’25n/a
Mex$3,970.91
0%
9.0%Mex$4,588.95Mex$3,144.28n/a21
May ’25Mex$2,852.19
Mex$3,859.97
+35.3%
7.0%Mex$4,411.10Mex$3,398.18n/a20
Apr ’25n/a
Mex$3,925.49
0%
7.0%Mex$4,488.53Mex$3,457.83n/a20
Mar ’25Mex$2,907.38
Mex$4,047.30
+39.2%
7.6%Mex$4,615.41Mex$3,555.57n/a20
Feb ’25n/a
Mex$3,989.56
0%
11.5%Mex$4,637.71Mex$2,799.80n/a20
Jan ’25n/a
Mex$3,861.49
0%
13.5%Mex$4,598.72Mex$2,776.26n/a20
Dec ’24Mex$3,243.00
Mex$3,767.33
+16.2%
16.1%Mex$4,796.96Mex$2,792.52n/a20
Nov ’24n/a
Mex$4,570.09
0%
21.1%Mex$6,448.26Mex$2,942.58n/a20
Oct ’24n/a
Mex$4,794.52
0%
17.5%Mex$6,232.10Mex$3,247.71n/a18
Sep ’24n/a
Mex$4,838.62
0%
15.0%Mex$5,970.04Mex$3,497.94n/a18
Aug ’24n/a
Mex$5,891.39
0%
8.7%Mex$6,397.50Mex$3,992.04n/a18
Jul ’24n/a
Mex$6,158.75
0%
8.6%Mex$6,676.01Mex$4,165.83n/a18
Jun ’24Mex$4,808.00
Mex$6,158.75
+28.1%
8.6%Mex$6,676.01Mex$4,165.83n/a18
May ’24n/a
Mex$6,082.80
0%
8.7%Mex$6,765.15Mex$4,221.45Mex$2,852.1917
Apr ’24n/a
Mex$5,965.41
0%
9.3%Mex$6,758.40Mex$4,217.24n/a16
Mar ’24n/a
Mex$5,951.33
0%
9.8%Mex$6,788.59Mex$4,236.08Mex$2,907.3816
Feb ’24Mex$5,363.75
Mex$5,963.66
+11.2%
11.7%Mex$6,698.06Mex$4,133.66n/a16
Jan ’24n/a
Mex$6,063.18
0%
12.0%Mex$6,846.91Mex$4,225.52n/a16
Dec ’23n/a
Mex$5,847.51
0%
12.0%Mex$6,774.11Mex$4,180.59Mex$3,243.0016

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 21:00
End of Day Share Price 2024/12/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Insulet Corporation is covered by 57 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anand VankawalaAvondale Partners
Jeffrey JohnsonBaird
Ishan MajumdarBaptista Research